Female Urology

"What we found is that 9% of women with a GSM-related diagnosis filled a prescription for vaginal estrogen during the study period, and these women tended to be younger," says Ekene Enemchukwu, MD, MPH, FACS, URPS.

“When I talk to physicians outside of urology, as well as within urology, much of the hesitation with using Cost Plus Drugs is that it seems complicated to use, when in reality, the process is actually very simple," says Raymond Xu, MD.

“To find a therapy that's all encompassing, that manages all of this in a long-term fashion, low-dose vaginal estrogen is the preferred treatment,” says Ekene Enemchukwu, MD, MPH, FACS, URPS.

“What's really cool about overactive bladder is that, it's not like high blood pressure. They do not have to leave this office with a pill in hand," says Anna Myers, CNP.

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.

The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.

"A lot of times…decreased desire is affected by everything else: pain with sex, orgasm, arousal. Because if none of that is good, then desire isn't going to be good either," says Anna Myers, CNP.

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.

Age, race, and hormonal contraceptive use did not significantly impact the efficacy of sildenafil cream, 3.6%, in female sexual arousal disorder.

"We had 66 respondents, and 48% of those did say that they had functionally limiting pelvic pain...for 14 days out of a given month at least," says Sarah Ponce.

“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

"You have to have a passion for it. If you have a passion for it, it's easy to do," says Shaya Taghechian, MD.

"I think pelvic pain is 1 of the areas that really needs more attention," says Gamal M. Ghoniem, MD, FACS, ABU/FPMRS.

"There is a severe lack of treatment when it comes to women's sexual health," says Shaya Taghechian, MD.

"When looking at individual vaginal estrogen products prescribed by OB-GYNs median spending per claim for Vagifem and Yuvafem decreased and median spending per claim increased for Estrace and Estring," says Alexandra Tabakin, MD.

Developed by the AUGS Scientific Committee and Research Agenda Writing Group

"Every time I leave the meeting, I just feel reinvigorated, refreshed, and excited about this field that we're a part of," says Raveen Syan, MD, FPMRS.

"I don't think 1 database study creates dogma, but I do think we can share these data with our patients and talk to them about treatment options and risk, have that difficult conversation about how BMI may be associated with that risk," says Cassandra K. Kisby, MD, MS.

"The most important thing that I think came out of this study is really the BMI inflection point for complications. We saw an abrupt rise in complications around a BMI of 40," says Cassandra K. Kisby, MD, MS.

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.

The aim of this document is to present a framework by which AUGS and its members can address the development of new technology and techniques, particularly in the surgical arena.

The FDA has issued a complete response letter regarding a new drug application for cefepime-taniborbactam for the treatment of patients with complicated urinary tract infection.

The position statement is meant to iterate AUGS' support for gender inclusion of both patients and health care providers.

Cefepime-taniborbactam is currently under review by the FDA for cUTI, including acute pyelonephritis, based on data from the CERTAIN-1 trial.

The purpose of this clinical consensus statement is to identify areas of expert consensus and nonconsensus regarding pessary fitting, follow-up, and management of pessary complications to improve the safety and quality of care where evidence is currently limited.

Iterum plans to resubmit a New Drug Application for oral sulopenem for the treatment of patients with uUTi in Q2 of 2024.

The goals of the American Urogynecologic Society (AUGS) program are to support novel clinical, translational, and bench research pilot projects and enable early career investigators to obtain future independent funding for research.